Resolve Therapeutics, LLC, a Seattle, WA-based biotechnology company focused on lupus therapy, has raised $2m in the first close of a Series A financing.
Investors include New Science Ventures and Easton Capital.
Led by CEO James Posada, Resolve is developing a novel targeted biologic therapy, RSLV-125, which is currently in advanced preclinical development. The company expects to begin human clinical studies with this compound in the near future.
In conjunction with the funding, Resolve also added:
– Peter Kiener, CEO of Zyngenia, as Chairman of the board.
– Somu Subramaniam, Founder and Managing Partner of New Science Ventures, as a member of the board.
– John Friedman, Managing Partner of Easton Capital, as an observer of the board.